CRISPR Therapeutics unites with ViaCyte to treat diabetes
19-09-2018
Vertex and CRISPR Therapeutics announce research partnership
26-10-2015
NicoElnino / iStockphoto.com
Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
MaxCyte, CRISPR, CRISPR Therapeutics, commercialisation, licence, gene editing, CRISPR/Cas9, immuno-oncology
